DK1295611T3 - Oligonukleotid-transformerende forbindelser - Google Patents

Oligonukleotid-transformerende forbindelser

Info

Publication number: DK1295611T3
Authority: DK; Denmark
Prior art keywords: oligonucleotide; transforming compounds; transforming; compounds; collagen
Prior art date: 2000-06-20

Application number

DK01938732.3T

Other languages

English (en)

Inventor

Shunichiro Kubota

Takahiro Ochiya

Hiroshi Itoh

Masayasu Furuse

Shunji Nagahara

Masaaki Terada

Akihiko Sano

Original Assignee

Dainippon Sumitomo Pharma Co

Koken Kk

Nat Cancer Ct

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-20

Filing date

2001-06-19

Publication date

2010-10-04

2001-06-19 Application filed by Dainippon Sumitomo Pharma Co, Koken Kk, Nat Cancer Ct filed Critical Dainippon Sumitomo Pharma Co

2010-10-04 Application granted granted Critical

2010-10-04 Publication of DK1295611T3 publication Critical patent/DK1295611T3/da

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 1
230000001131 transforming effect Effects 0.000 title 1
102000008186 Collagen Human genes 0.000 abstract 1
108010035532 Collagen Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
210000004102 animal cell Anatomy 0.000 abstract 1
230000000692 anti-sense effect Effects 0.000 abstract 1
229920001436 collagen Polymers 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

DK01938732.3T 2000-06-20 2001-06-19 Oligonukleotid-transformerende forbindelser DK1295611T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2000184502		2000-06-20
PCT/JP2001/005195 WO2001097857A1 (fr)	2000-06-20	2001-06-19	Preparations destinees au transfert d'oligonucleotides

Publications (1)

Publication Number	Publication Date
DK1295611T3 true DK1295611T3 (da)	2010-10-04

Family

ID=18684937

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01938732.3T DK1295611T3 (da)	2000-06-20	2001-06-19	Oligonukleotid-transformerende forbindelser

Country Status (10)

Country	Link
US (3)	US20040052840A1 (da)
EP (1)	EP1295611B1 (da)
JP (1)	JP5118285B2 (da)
AT (1)	ATE478688T1 (da)
AU (1)	AU2001264317A1 (da)
DE (1)	DE60142899D1 (da)
DK (1)	DK1295611T3 (da)
ES (1)	ES2349137T3 (da)
PT (1)	PT1295611E (da)
WO (1)	WO2001097857A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW586934B (en) *	1997-05-19	2004-05-11	Sumitomo Pharma	Immunopotentiating composition
AU2001264317A1 (en) *	2000-06-20	2002-01-02	Koken Co., Ltd.	Preparations for oligonucleotide transfer
DE60232149D1 (de) *	2001-06-20	2009-06-10	Dainippon Sumitomo Pharma Co	Verfahren zur förderung des nukleinsäuretransfers
US20100104631A1 (en) *	2001-08-13	2010-04-29	Lipella Pharmaceuticals Inc.	Method of treatment for bladder dysfunction
JPWO2004026343A1 (ja) *	2002-09-20	2006-01-12	住友製薬株式会社	部位特異的遺伝子変換促進剤および遺伝子疾患治療剤
WO2005061717A1 (ja) *	2003-12-19	2005-07-07	Dainippon Sumitomo Pharma Co., Ltd.	新規な核酸導入法
US20090062184A1 (en) *	2005-03-24	2009-03-05	Dainippon Sumitomo Pharma Co., Ltd.	Fine particulate preparation comprising complex of nucleic acid molecule and collagen
US7838502B2 (en) *	2005-05-06	2010-11-23	University Of Massachusetts Medical School	Compositions and methods to modulate H. influenzae pathogenesis
JPWO2006126600A1 (ja) *	2005-05-25	2008-12-25	国立大学法人名古屋大学	血管閉塞性疾患用医薬組成物
KR100777249B1 (ko)	2006-02-14	2007-11-28	(주)바이오니아	건조 올리고뉴클레오티드 조성물 및 이의 제조 방법
WO2010078403A2 (en) *	2008-12-30	2010-07-08	Lipella Pharmaceuticals Inc.	Methods and compositions for diagnosing urological disorders
FR3066115B1 (fr)	2017-05-10	2019-06-28	Universite de Bordeaux	Comprimes de vecteurs d'acides nucleiques

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5115094B2 (da) *	1972-11-01	1976-05-14
US5069936A (en) *	1987-06-25	1991-12-03	Yen Richard C K	Manufacturing protein microspheres
US5078997A (en) *	1988-07-13	1992-01-07	Cetus Corporation	Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5098890A (en) *	1988-11-07	1992-03-24	Temple University-Of The Commonwealth System Of Higher Education	Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5614587A (en) *	1988-11-21	1997-03-25	Collagen Corporation	Collagen-based bioadhesive compositions
US5936035A (en) *	1988-11-21	1999-08-10	Cohesion Technologies, Inc.	Biocompatible adhesive compositions
JP3187410B2 (ja) *	1989-08-10	2001-07-11	住友製薬株式会社	脳内投与用徐放性製剤
US5542935A (en) *	1989-12-22	1996-08-06	Imarx Pharmaceutical Corp.	Therapeutic delivery systems related applications
US5264618A (en) *	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
FR2694895B1 (fr) *	1992-08-20	1994-11-10	Coletica	Procédé de fabrication de microparticules en émulsion par modification de la composition chimique de la phase dispersée après émulsification.
US5646042A (en) *	1992-08-26	1997-07-08	Ribozyme Pharmaceuticals, Inc.	C-myb targeted ribozymes
AU682877B2 (en) *	1993-05-28	1997-10-23	Chiron Corporation	Peptide inhibitors of urokinase receptor activity
DE59409568D1 (de) *	1993-09-09	2000-11-30	Schering Ag	Wirkstoffe und gas enthaltende mikropartikel
CA2140053C (en) *	1994-02-09	2000-04-04	Joel S. Rosenblatt	Collagen-based injectable drug delivery system and its use
US5942496A (en) *	1994-02-18	1999-08-24	The Regent Of The University Of Michigan	Methods and compositions for multiple gene transfer into bone cells
US5583034A (en) *	1994-02-22	1996-12-10	La Jolla Institute For Allergy And Immunology	Enhancement of adoptosis using antisense oligonucleotides
US5844107A (en) *	1994-03-23	1998-12-01	Case Western Reserve University	Compacted nucleic acids and their delivery to cells
US5563255A (en) *	1994-05-31	1996-10-08	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of raf gene expression
AU2946295A (en) *	1994-06-27	1996-01-19	Johns Hopkins University, The	Targeted gene delivery system
US6998268B2 (en) *	1995-07-03	2006-02-14	Dainippon Sumitomo Pharma Co. Ltd.	Gene preparations
DE69637243T2 (de) *	1995-07-03	2008-06-19	Dainippon Sumitomo Pharma Co., Ltd.	Atelocollagen enthaltende gen-zusammensetzungen
JP3867160B2 (ja) *	1995-07-03	2007-01-10	大日本住友製薬株式会社	遺伝子製剤
NZ320006A (en) *	1995-10-23	2001-12-21	Meditech Res Ltd	An adjuvant composition comprising hyaluronic acid for gene therapy either in the sense or antisense direction
EP1704878B1 (en) *	1995-12-18	2013-04-10	AngioDevice International GmbH	Crosslinked polymer compositions and methods for their use
JP2000506865A (ja) *	1996-03-14	2000-06-06	ジイミューンリスポンスコーポレイション	インターフェロンをコードする遺伝子の標的を定めた送達
US6133437A (en) *	1997-02-13	2000-10-17	Apoptogen, Inc.	Modulation of IAPs for the treatment of proliferative diseases
US5874006A (en) *	1996-10-31	1999-02-23	Matrix Pharmaceutical, Inc.	Aseptic collagen concentration process
US6042820A (en) *	1996-12-20	2000-03-28	Connaught Laboratories Limited	Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6218112B1 (en) *	1996-12-23	2001-04-17	Cobra Therapeutics Limited	Optimization of gene delivery and gene delivery system
EP2256133B1 (en) *	1997-01-08	2016-12-14	Sigma-Aldrich Co. LLC	Bioconjugation of macromolecules
US6524613B1 (en) *	1997-04-30	2003-02-25	Regents Of The University Of Minnesota	Hepatocellular chimeraplasty
AU2868099A (en) *	1998-02-13	1999-08-30	Selective Genetics, Inc.	Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
NZ508785A (en) *	1998-05-22	2003-10-31	Sumitomo Pharma	Stable gene formulations
HK1054184A1 (zh) *	2000-03-31	2003-11-21	Trustees Of Boston University	局部應用dna片斷的用途
AU2001264317A1 (en) *	2000-06-20	2002-01-02	Koken Co., Ltd.	Preparations for oligonucleotide transfer
JP2002325572A (ja) *	2000-12-25	2002-11-12	Univ Osaka	外来物質の導入方法
DE60232149D1 (de) *	2001-06-20	2009-06-10	Dainippon Sumitomo Pharma Co	Verfahren zur förderung des nukleinsäuretransfers
US7148342B2 (en) *	2002-07-24	2006-12-12	The Trustees Of The University Of Pennyslvania	Compositions and methods for sirna inhibition of angiogenesis
JP4754216B2 (ja) *	2002-09-04	2011-08-24	ノバルティスアーゲー	ｄｓＲＮＡ投与による神経疾患の処置
JPWO2004026343A1 (ja) *	2002-09-20	2006-01-12	住友製薬株式会社	部位特異的遺伝子変換促進剤および遺伝子疾患治療剤
KR20120038546A (ko) *	2002-11-01	2012-04-23	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
MXPA05007651A (es) *	2003-01-16	2005-10-26	Univ Pennsylvania	Composiciones y metodos para la inhibicion por arnsi de la molecula de adhesion intercelular-1.
US8227434B1 (en) *	2003-11-04	2012-07-24	H. Lee Moffitt Cancer Center & Research Institute, Inc.	Materials and methods for treating oncological disorders
WO2005082070A2 (en) *	2004-02-26	2005-09-09	Baylor Research Institute	Compositions and methods for the systemic treatment of arthritis
JP4991547B2 (ja) *	2004-09-28	2012-08-01	クアーク・ファーマスーティカルス、インコーポレイテッド	脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
JP2008516993A (ja) *	2004-10-22	2008-05-22	ユニベルシテラバル	疼痛の治療および予防における神経膠細胞由来ｂｄｎｆの調節
US7585848B2 (en) *	2005-01-11	2009-09-08	Rush University Medical Center	Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
EP1983823A1 (en) *	2006-01-17	2008-10-29	VIB vzw	Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
CA2655355C (en) *	2006-06-16	2014-05-06	Taisho Pharmaceutical Co., Ltd.	Use of rpn2 gene expression inhibitor
CN101490253A (zh) *	2006-07-21	2009-07-22	赛伦斯治疗公司	用于抑制蛋白激酶3表达的方法
WO2008028085A2 (en) *	2006-08-30	2008-03-06	The Board Of Trustees Of The University Of Illinois	Modulation of mlck-l expression and uses thereof
WO2008041933A2 (en) *	2006-10-02	2008-04-10	Aprea Ab	Rna interference against wrap53 to treat hyperproliferative diseases
US7812002B2 (en) *	2007-03-21	2010-10-12	Quark Pharmaceuticals, Inc.	Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
US8227444B2 (en) *	2009-12-04	2012-07-24	Opko Ophthalmics, Llc	Compositions and methods for inhibition of VEGF

2001
- 2001-06-19 AU AU2001264317A patent/AU2001264317A1/en not_active Abandoned
- 2001-06-19 ES ES01938732T patent/ES2349137T3/es not_active Expired - Lifetime
- 2001-06-19 DK DK01938732.3T patent/DK1295611T3/da active
- 2001-06-19 JP JP2002503340A patent/JP5118285B2/ja not_active Expired - Fee Related
- 2001-06-19 AT AT01938732T patent/ATE478688T1/de active
- 2001-06-19 EP EP01938732A patent/EP1295611B1/en not_active Expired - Lifetime
- 2001-06-19 PT PT01938732T patent/PT1295611E/pt unknown
- 2001-06-19 US US10/311,621 patent/US20040052840A1/en not_active Abandoned
- 2001-06-19 WO PCT/JP2001/005195 patent/WO2001097857A1/ja not_active Ceased
- 2001-06-19 DE DE60142899T patent/DE60142899D1/de not_active Expired - Lifetime
2009
- 2009-06-17 US US12/486,703 patent/US20090258933A1/en not_active Abandoned
2010
- 2010-10-13 US US12/904,054 patent/US20110028535A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20110028535A1 (en)	2011-02-03
PT1295611E (pt)	2010-09-14
WO2001097857A1 (fr)	2001-12-27
ATE478688T1 (de)	2010-09-15
EP1295611B1 (en)	2010-08-25
US20090258933A1 (en)	2009-10-15
JP5118285B2 (ja)	2013-01-16
EP1295611A4 (en)	2009-07-08
DE60142899D1 (de)	2010-10-07
ES2349137T3 (es)	2010-12-28
AU2001264317A1 (en)	2002-01-02
EP1295611A1 (en)	2003-03-26
US20040052840A1 (en)	2004-03-18

Publication	Publication Date	Title
PT1459751E (pt)	2005-11-30	(s,s)-reboxetina para tratar as enxaquecas
WO2002036743A3 (en)	2003-01-16	Antisense modulation of calreticulin expression
ATE263354T1 (de)	2004-04-15	Vorrichtung zur herstellung von kontaktkörpern
EP1569695A4 (en)	2006-12-06	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
AP2210A (en)	2011-02-25	4-tetrazolyl-4phenylpiperidine derivatives for treating pain.
MXPA03009645A (es)	2004-01-29	Proceso para preparar oxazolidinonas.
MXPA03003632A (es)	2003-09-10	Metodo para tratamiento de tumores usando terapia de combinacion.
DK1295611T3 (da)	2010-10-04	Oligonukleotid-transformerende forbindelser
EP1648910A4 (en)	2008-02-27	ANTISENSE MODULATION OF THE EXPRESSION OF STEAROYL COA DESATURASE
WO2001029175A3 (en)	2001-10-11	Antisense modulation of fra-1 expression
AU2180501A (en)	2001-06-12	Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
WO2004010956A3 (en)	2004-07-01	Antisense modulation of lar expression
ES1044983Y (es)	2000-12-16	Aparato de termoestimulacion para tratamientos terapeuticos.
EP1642884A4 (en)	2007-12-26	PROCESS FOR PREPARING OPTICALLY ACTIVE 1-ALKYL SUBSTITUTED 2,2,2-TRIFLUORETHYLAMINE
WO2003027229A3 (en)	2004-03-11	Antisense modulation of rip2 expression
IT1311624B1 (it)	2002-03-14	Apparato per il trattamento di piantagioni in filari.
WO2003044167A3 (en)	2004-02-12	Antisense modulation of human fxr expression
WO2002041836A3 (en)	2002-08-29	Antisense modulation of src-1 expression
WO2004001061A3 (en)	2006-02-23	Antisense modulation of heme oxygenase 1 expression
WO2003033659A3 (en)	2004-03-25	Antisense modulation of matrix metalloproteinase 1 expression
ES1045858Y (es)	2001-04-01	Maquina para tratamiento de aceitunas.
WO2002040637A3 (en)	2003-02-27	Antisense modulation of pi3k p85 expression
WO2002055535A3 (en)	2002-10-31	Antisense modulation of cytohesin-1 expression
WO2004015126A3 (en)	2004-07-01	Antisense modulation of edg1 expression
WO2003099204A3 (en)	2004-02-26	Antisense modulation of inhibitor-kappa b kinase-beta expression